APO RESEARCH · REPORT
Liposomes Drug Delivery
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
Product & engineering
Understand the product.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
Selected research
Industry Research
Liposomes Drug Delivery Industry Research Report 2026
Market perspective
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
North America dominated the market with market share of 44% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12%.
Read the full market overview
Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma and Sigma-Tau Group are the top 6 players of Liposomes Drug Delivery, with about 77% market shares.
Report Scope
This report quantifies the global Liposomes Drug Delivery market in terms of revenue (US$ million) and, where applicable, sales volume (K Vials), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Vials) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liposomes Drug Delivery Market by Company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia
Liposomes Drug Delivery Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Liposomes Drug Delivery Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
Liposomes Drug Delivery Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomes Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomes Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomes Drug Delivery.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liposomes Drug Delivery manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liposomes Drug Delivery by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liposomes Drug Delivery in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Applications
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
Companies covered
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
- Spectrum Pharmaceuticals
- Shanghai New Asia
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liposomes Drug Delivery Market Size (2021-2032)
- 2.2.2 Global Liposomes Drug Delivery Sales (2021-2032)
- 2.2.3 Global Liposomes Drug Delivery Market Average Price (2021-2032)
- 2.3 Liposomes Drug Delivery by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Liposomal Doxorubicin
- 2.3.3 Liposomal Amphoteracin B
- 2.3.4 Liposomal Paclitaxel
- 2.3.5 Others
- 2.4 Liposomes Drug Delivery by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Fungal Infection Therapy
- 2.4.3 Cancer & Tumor Therapy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liposomes Drug Delivery Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liposomes Drug Delivery Sales (K Vials) of Manufacturers (2021-2026)
- 3.3 Global Liposomes Drug Delivery Revenue of Manufacturers (2021-2026)
- 3.4 Global Liposomes Drug Delivery Average Price by Manufacturers (2021-2026)
- 3.5 Global Liposomes Drug Delivery Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liposomes Drug Delivery, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liposomes Drug Delivery, Product Type & Application
- 3.8 Global Manufacturers of Liposomes Drug Delivery, Established Date
- 3.9 Global Liposomes Drug Delivery Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Liposomes Drug Delivery Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Gilead Sciences
- 4.2.1 Gilead Sciences Company Information
- 4.2.2 Gilead Sciences Business Overview
- 4.2.3 Gilead Sciences Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Gilead Sciences Liposomes Drug Delivery Product Portfolio
- 4.2.5 Gilead Sciences Recent Developments
- 4.3 Pacira
- 4.3.1 Pacira Company Information
- 4.3.2 Pacira Business Overview
- 4.3.3 Pacira Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pacira Liposomes Drug Delivery Product Portfolio
- 4.3.5 Pacira Recent Developments
- 4.4 Sun Pharmaceutical
- 4.4.1 Sun Pharmaceutical Company Information
- 4.4.2 Sun Pharmaceutical Business Overview
- 4.4.3 Sun Pharmaceutical Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharmaceutical Liposomes Drug Delivery Product Portfolio
- 4.4.5 Sun Pharmaceutical Recent Developments
- 4.5 Luye Pharma
- 4.5.1 Luye Pharma Company Information
- 4.5.2 Luye Pharma Business Overview
- 4.5.3 Luye Pharma Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Luye Pharma Liposomes Drug Delivery Product Portfolio
- 4.5.5 Luye Pharma Recent Developments
- 4.6 Sigma-Tau Group
- 4.6.1 Sigma-Tau Group Company Information
- 4.6.2 Sigma-Tau Group Business Overview
- 4.6.3 Sigma-Tau Group Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sigma-Tau Group Liposomes Drug Delivery Product Portfolio
- 4.6.5 Sigma-Tau Group Recent Developments
- 4.7 Fudan-Zhangjiang
- 4.7.1 Fudan-Zhangjiang Company Information
- 4.7.2 Fudan-Zhangjiang Business Overview
- 4.7.3 Fudan-Zhangjiang Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Fudan-Zhangjiang Liposomes Drug Delivery Product Portfolio
- 4.7.5 Fudan-Zhangjiang Recent Developments
- 4.8 Teva Pharmaceutical
- 4.8.1 Teva Pharmaceutical Company Information
- 4.8.2 Teva Pharmaceutical Business Overview
- 4.8.3 Teva Pharmaceutical Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Pharmaceutical Liposomes Drug Delivery Product Portfolio
- 4.8.5 Teva Pharmaceutical Recent Developments
- 4.9 CSPC
- 4.9.1 CSPC Company Information
- 4.9.2 CSPC Business Overview
- 4.9.3 CSPC Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSPC Liposomes Drug Delivery Product Portfolio
- 4.9.5 CSPC Recent Developments
- 4.10 Novartis
- 4.10.1 Novartis Company Information
- 4.10.2 Novartis Business Overview
- 4.10.3 Novartis Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Novartis Liposomes Drug Delivery Product Portfolio
- 4.10.5 Novartis Recent Developments
- 4.11 Kingond Pharm
- 4.11.1 Kingond Pharm Company Information
- 4.11.2 Kingond Pharm Business Overview
- 4.11.3 Kingond Pharm Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Kingond Pharm Liposomes Drug Delivery Product Portfolio
- 4.11.5 Kingond Pharm Recent Developments
- 4.12 Spectrum Pharmaceuticals
- 4.12.1 Spectrum Pharmaceuticals Company Information
- 4.12.2 Spectrum Pharmaceuticals Business Overview
- 4.12.3 Spectrum Pharmaceuticals Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Spectrum Pharmaceuticals Liposomes Drug Delivery Product Portfolio
- 4.12.5 Spectrum Pharmaceuticals Recent Developments
- 4.13 Shanghai New Asia
- 4.13.1 Shanghai New Asia Company Information
- 4.13.2 Shanghai New Asia Business Overview
- 4.13.3 Shanghai New Asia Liposomes Drug Delivery Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shanghai New Asia Liposomes Drug Delivery Product Portfolio
- 4.13.5 Shanghai New Asia Recent Developments
5 Global Liposomes Drug Delivery Market Scenario by Region
- 5.1 Global Liposomes Drug Delivery Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liposomes Drug Delivery Sales by Region: 2021-2032
- 5.2.1 Global Liposomes Drug Delivery Sales by Region: 2021-2026
- 5.2.2 Global Liposomes Drug Delivery Sales by Region: 2027-2032
- 5.3 Global Liposomes Drug Delivery Revenue by Region: 2021-2032
- 5.3.1 Global Liposomes Drug Delivery Revenue by Region: 2021-2026
- 5.3.2 Global Liposomes Drug Delivery Revenue by Region: 2027-2032
- 5.4 North America Liposomes Drug Delivery Market Facts & Figures by Country
- 5.4.1 North America Liposomes Drug Delivery Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liposomes Drug Delivery Sales by Country (2021-2032)
- 5.4.3 North America Liposomes Drug Delivery Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Liposomes Drug Delivery Market Facts & Figures by Country
- 5.5.1 Europe Liposomes Drug Delivery Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liposomes Drug Delivery Sales by Country (2021-2032)
- 5.5.3 Europe Liposomes Drug Delivery Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Liposomes Drug Delivery Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liposomes Drug Delivery Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liposomes Drug Delivery Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liposomes Drug Delivery Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liposomes Drug Delivery Market Facts & Figures by Country
- 5.7.1 South America Liposomes Drug Delivery Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liposomes Drug Delivery Sales by Country (2021-2032)
- 5.7.3 South America Liposomes Drug Delivery Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Liposomes Drug Delivery Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liposomes Drug Delivery Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liposomes Drug Delivery Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liposomes Drug Delivery Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Liposomes Drug Delivery Sales by Type (2021-2032)
- 6.1.1 Global Liposomes Drug Delivery Sales by Type (2021-2032) & (K Vials)
- 6.1.2 Global Liposomes Drug Delivery Sales Market Share by Type (2021-2032)
- 6.2 Global Liposomes Drug Delivery Revenue by Type (2021-2032)
- 6.2.1 Global Liposomes Drug Delivery Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liposomes Drug Delivery Revenue Market Share by Type (2021-2032)
- 6.3 Global Liposomes Drug Delivery Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liposomes Drug Delivery Sales by Application (2021-2032)
- 7.1.1 Global Liposomes Drug Delivery Sales by Application (2021-2032) & (K Vials)
- 7.1.2 Global Liposomes Drug Delivery Sales Market Share by Application (2021-2032)
- 7.2 Global Liposomes Drug Delivery Revenue by Application (2021-2032)
- 7.2.1 Global Liposomes Drug Delivery Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liposomes Drug Delivery Revenue Market Share by Application (2021-2032)
- 7.3 Global Liposomes Drug Delivery Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liposomes Drug Delivery Value Chain Analysis
- 8.1.1 Liposomes Drug Delivery Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liposomes Drug Delivery Production Mode & Process
- 8.2 Liposomes Drug Delivery Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liposomes Drug Delivery Distributors
- 8.2.3 Liposomes Drug Delivery Customers
9 Global Liposomes Drug Delivery Analyzing Market Dynamics
- 9.1 Liposomes Drug Delivery Industry Trends
- 9.2 Liposomes Drug Delivery Industry Drivers
- 9.3 Liposomes Drug Delivery Industry Opportunities and Challenges
- 9.4 Liposomes Drug Delivery Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst